Literature DB >> 27848179

Human MutT homologue 1 mRNA overexpression correlates to poor response of multiple myeloma.

Huixing Zhou1, Yuan Jian1, Yun Leng1, Nian Liu1, Ying Tian1, Guorong Wang1, Wen Gao1, Guangzhong Yang1, Wenming Chen2.   

Abstract

Human MutT homologue 1 (MTH1) is a human 8-oxo-dGTPase that eradicates oxidized bases in the nucleotide pool and DNA. MTH1 is critical for RAS-transformed cancer cell survival, whereas it is dispensable in normal cells and tissues. Here, we determined the expression of MTH1 in multiple myeloma (MM) cell lines and MM patients' CD138 (+) cells and analyzed its potential clinical significance. We detected overexpression of MTH1 mRNA in three cell lines (RPMI 8226, U266, and H929). MTH1 mRNA expression of RPMI8226 was higher than that of U266 and H929. In 59 MM patients, overexpression of MTH1 mRNA was detected in 27 cases (45.7%). MTH1 mRNA expression was significantly higher in ISS III stage (P < 0.001) and refractory relapse patients (P < 0.05). MTH1 mRNA expression in patients achieving less than partial response (PR) was significantly higher than in those achieving PR and better in newly diagnosed MM (P = 0.04). In conclusion, higher MTH1 may be associated with later disease stage and advanced disease progression. MTH1 mRNA overexpression is also correlated poor efficacy of bortezomib in newly diagnosed MM patients.

Entities:  

Keywords:  Bortezomib; MTH1; Multiple myeloma

Mesh:

Substances:

Year:  2016        PMID: 27848179     DOI: 10.1007/s12185-016-2139-3

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  43 in total

1.  Mutation analysis of the hMTH1 gene in sporadic human ovarian cancer.

Authors:  F Takama; T Kanuma; D Wang; J I Nishida; Y Nakabeppu; N Wake; H Mizunuma
Journal:  Int J Oncol       Date:  2000-09       Impact factor: 5.650

Review 2.  Manipulation of cellular redox parameters for improving therapeutic responses in B-cell lymphoma and multiple myeloma.

Authors:  Apollina Goel; Douglas R Spitz; George J Weiner
Journal:  J Cell Biochem       Date:  2012-02       Impact factor: 4.429

3.  Clinical and biological significance of RAS mutations in multiple myeloma.

Authors:  W J Chng; N Gonzalez-Paz; T Price-Troska; S Jacobus; S V Rajkumar; M M Oken; R A Kyle; K J Henderson; S Van Wier; P Greipp; B Van Ness; R Fonseca
Journal:  Leukemia       Date:  2008-06-05       Impact factor: 11.528

4.  Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death.

Authors:  Li Yin; Turner Kufe; David Avigan; Donald Kufe
Journal:  Blood       Date:  2014-03-14       Impact factor: 22.113

5.  Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias.

Authors:  P Corradini; M Ladetto; C Voena; A Palumbo; G Inghirami; D M Knowles; M Boccadoro; A Pileri
Journal:  Blood       Date:  1993-05-15       Impact factor: 22.113

6.  Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors.

Authors:  Thomas Rasmussen; Michael Kuehl; Marianne Lodahl; Hans E Johnsen; Inger Marie S Dahl
Journal:  Blood       Date:  2004-08-31       Impact factor: 22.113

7.  Expression of DNA repair protein: MYH, NTH1, and MTH1 in colorectal cancer.

Authors:  Shinichiro Koketsu; Toshiaki Watanabe; Hirokazu Nagawa
Journal:  Hepatogastroenterology       Date:  2004 May-Jun

8.  Overexpression of human mutT homologue gene messenger RNA in renal-cell carcinoma: evidence of persistent oxidative stress in cancer.

Authors:  K Okamoto; S Toyokuni; W J Kim; O Ogawa; Y Kakehi; S Arao; H Hiai; O Yoshida
Journal:  Int J Cancer       Date:  1996-02-08       Impact factor: 7.396

9.  Cancer phenotypic lethality, exemplified by the non-essential MTH1 enzyme being required for cancer survival.

Authors:  T Helleday
Journal:  Ann Oncol       Date:  2014-04-15       Impact factor: 32.976

10.  Bortezomib (Velcadetrade mark) in the Treatment of Multiple Myeloma.

Authors:  Antonia Field-Smith; Gareth J Morgan; Faith E Davies
Journal:  Ther Clin Risk Manag       Date:  2006-09       Impact factor: 2.423

View more
  4 in total

1.  The Existence of MTH1-independent 8-oxodGTPase Activity in Cancer Cells as a Compensatory Mechanism against On-target Effects of MTH1 Inhibitors.

Authors:  Govindi J Samaranayake; Clara I Troccoli; Ling Zhang; Mai Huynh; Christina J Jayaraj; Debin Ji; Lisa McPherson; Yoshiyuki Onishi; Dao M Nguyen; David J Robbins; Mahsa Karbaschi; Marcus S Cooke; Antonio Barrientos; Eric T Kool; Priyamvada Rai
Journal:  Mol Cancer Ther       Date:  2019-11-19       Impact factor: 6.261

2.  Potent and specific MTH1 inhibitors targeting gastric cancer.

Authors:  Wenjuan Zhou; Liying Ma; Jing Yang; Hui Qiao; Lingyu Li; Qian Guo; Jinlian Ma; Lijuan Zhao; Junwei Wang; Guozhong Jiang; Xiangbin Wan; Mariusz Adam Goscinski; Lina Ding; Yichao Zheng; Wencai Li; Hongmin Liu; Zhenhe Suo; Wen Zhao
Journal:  Cell Death Dis       Date:  2019-06-04       Impact factor: 8.469

3.  Radiolabeled 6-(2, 3-Dichlorophenyl)-N4-methylpyrimidine-2, 4-diamine (TH287): A Potential Radiotracer for Measuring and Imaging MTH1.

Authors:  Huaping Chen; Sadia Afrin; Yingqiu Guo; Wenhua Chu; Tammie L S Benzinger; Buck E Rogers; Joel R Garbow; Joel S Perlmutter; Dong Zhou; Jinbin Xu
Journal:  Int J Mol Sci       Date:  2020-11-23       Impact factor: 5.923

4.  The role of miR-485-5p/NUDT1 axis in gastric cancer.

Authors:  Jingjing Duan; Haiyang Zhang; Shuang Li; Xinyi Wang; Haiou Yang; Shunchang Jiao; Yi Ba
Journal:  Cancer Cell Int       Date:  2017-10-17       Impact factor: 5.722

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.